Testing a new pancreatic cancer drug delivery method

Plain-English translation of NCT06752811 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new form of paclitaxel polymeric micelles—a cancer medication delivered in tiny particles designed to work better in the body—combined with gemcitabine chemotherapy. The study compares this new version to the current standard treatment (albumin-bound paclitaxel plus gemcitabine) in patients with metastatic pancreatic cancer that has not been treated before. Researchers hope this new approach will help patients live longer and healthier lives.

Pancreatic cancer that has spread is very serious, and current treatments have limited effectiveness. The new medication delivery method is designed to get the drug to cancer cells more effectively while potentially causing fewer side effects, which could improve survival and quality of life for patients.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with metastatic pancreatic cancer confirmed by biopsy or cell sample
you have not received any previous chemotherapy, targeted therapy, immunotherapy, or radiation for metastatic pancreatic cancer (though you may qualify if you had treatment before the cancer returned, as long as it's been more than 6 months)
you are in good enough general health to receive chemotherapy (an ECOG performance status of 0–2)
your blood counts, liver function, and kidney function are within acceptable ranges

You likely don't qualify if…

you are allergic to paclitaxel, gemcitabine, or similar drugs
you have had another cancer within the past 5 years (except for easily cured skin cancers or thyroid cancers)
you have cancer that has spread to your brain or spinal fluid
you are pregnant or nursing, or unwilling to use effective birth control during and after treatment
you have severe organ damage or serious medical conditions that would make chemotherapy unsafe

What participation looks like

You will be randomly assigned to receive either the new medication or the standard treatment, both given intravenously (through an IV) in combination with gemcitabine chemotherapy. The experimental group receives the new medication once every 3 weeks, while the standard group receives its medication on a different schedule (Days 1, 8, and 15 of each 4-week cycle). You will have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and watch for side effects. Treatment typically continues until the cancer grows, you cannot tolerate the medication, or your doctor determines it is no longer helping.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(2 sites)

China

Jiangsu Province Hospital, Nanjing, Jiangsu

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality